Alström syndrome is a rare genetic syndrome associated with early-onset obesity, severe insulin resistance (IR) that is disproportionate to the degree of adiposity and premature diabetes. The ALMS1 gene, which is mutated in Alström syndrome, encodes a giant 460 kDa centrosome-and basal body-associated protein. Its function is unknown, although roles in primary cilia formation and function, intracellular organelle trafficking and, most recently, adipocyte differentiation have been mooted. We now test the hypothesis that the severe IR and dyslipidaemia in Alström syndrome are accounted for by a partial defect in adipogenesis and/or insulin action in mature adipocytes, leading to relative failure of adipose tissue to discharge its role in metabolic homeostasis. Stable knockdown of Alms1 expression by 480% in 3T3-L1 preadipocytes was associated with impairment of lipid accumulation and at least a twofold reduction in adipocyte gene expression following hormonal induction of adipogenesis. This was accompanied by a commensurate defect in insulin-stimulated glucose uptake. Proximal signalling events in response to insulin were unaffected. These results suggest that partial impairment of adipogenesis in Alström syndrome may contribute to the severity of the associated metabolic phenotype, whereas the ability of insulin to stimulate glucose uptake into adipocytes is grossly unimpaired.
Introduction
The rising global tide of obesity is generating international concern because of its intimate association with type 2 diabetes, premature atherosclerosis and liver disease. Insulin resistance (IR) is the central mediator of these phenomena, yet how exactly IR arises in the context of obesity remains uncertain. Key insights have been gained from rare conditions in which single gene defects lead to severe abnormalities in adipose tissue mass. Thus, genetic disorders featuring defects in adipose tissue generation, producing clinical lipodystrophy, are associated with unusually severe forms of the metabolic syndrome, demonstrating that a healthy adipose buffer is essential to metabolic health. 1 At the other end of the spectrum, severe genetically-determined hyperphagia leads to extreme obesity in which even a healthy adipose tissue reserve is overwhelmed by the demands placed on excessive caloric loads. 2 These observations have led to the suggestion that in milder obesity it is relative 'fat failure', much of it genetically determined, which accounts for the highly prevalent metabolic syndrome and/or IR. 3 However, no human monogenic models of such a phenomenon have been described. Alström syndrome (OMIM#203800) is an autosomal-recessive disorder featuring progressive retinal dystrophy, sensorineural deafness, cardiomyopathy and moderate obesity. Severe IR, diabetes and dyslipidaemia, resembling an extreme form of the common metabolic syndrome are also nearly invariably found. 4 Furthermore, even when carefully matched for pubertal stage and body composition, patients with Alström syndrome are much more severely insulin resistant than controls. 5 One interpretation is that Alström syndrome leads to relative adipose failure without frank lipodystrophy.
Alström syndrome is caused by biallelic mutations in ALMS1, which encodes a 460 kDa, ubiquitously expressed centrosomal/basal body protein. [6] [7] [8] Although this suggests that it is involved in the cellular functions of these organelles, namely, cell division, microtubule organization, intracellular transport and primary cilia function, its precise molecular role remains elusive. We now test the hypothesis that ALMS1 has a role in adipose tissue, either in the differentiation of healthy adipocytes from precursors, or in mediating insulin action on glucose uptake, which involves a series of vesicle-trafficking events. Disruption of either of these functions in vivo could explain the disproportionate IR of Alström syndrome.
To test these hypotheses, we knocked down Alms1 expression in murine 3T3-L1 preadipocytes using stable expression of specific short hairpin RNAs (shRNAs). Briefly, two shRNA constructs targeting Alms1 ('shAlms1-1'; exon 4; 5 0 -GCCTGATTCCTTGTTTCAA-3 0 and 'shAlms1-2'; exon 10; 5 0 -CAGAATAGCCAGATAGTAA-3 0 ) and one targeting firefly luciferase as a control ('shLuc') were cloned into the RNAiReady pSIREN-RetroQ Vector (Clontech, Palo Alto, CA, USA). Infectious retroviruses were generated in BOSC-HEK293 packaging cells (from Dr J Rochford, University of Cambridge) before infection of 3T3-L1 preadipocytes (American Tissue Culture Collection). 9 Preadipocytes were maintained in Dulbecco's modified Eagle's medium supplemented with 10% neonatal calf serum, 100 U l À1 penicillin, 100 mg ml À1 streptomycin, 4 mM L-glutamine and 4 mg ml À1 puromycin (Sigma, St Louis, MO, USA). Cells were grown to confluence and differentiated as previously described 10 with 100 nM rosiglitazone (Sigma) present at all stages. Differentiation was assessed by staining formalin-fixed adipocytes with Oil-Red-O. 9 Total RNA was extracted using the RNEasy kit (Qiagen, Crawley, UK). Alms1, Pparg2, Fabp4 (ap2), Insr, Glut4 and AdipoQ mRNA expression was quantified after reverse transcription using quantitative real-time PCR on an ABI 7900 detection system (Applied Biosystems, Foster City, CA, USA) and Taqman PCR Master Mix (Applied Biosystems). All results were normalized to levels of Ppia (cyclophilin A). Oligonucleotide sequences are shown in Supplementary  Table 1 . Insulin-stimulated glucose uptake was determined by exposing serum-starved adipocytes to 100 nM insulin (Novo Nordisk, Bagsvaerd, Denmark) or phosphate-buffered saline (PBS) in glucose-free HEPES buffer for 30 min followed by incubation in 1 uCi ml
H-deoxyglucose (Sigma-Aldrich) for 5 min and subsequent measurement of intracellular 3 H.
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To evaluate proximal insulin signalling, adipocytes were serum starved for 14 h before treatment with 100 nM insulin or PBS for 5 min. Cells were lysed on ice in a buffer containing 50 mM pH 7.4 HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 150 nM sodium chloride, 30 mM sodium fluoride, 1 mM sodium pyrophosphate, 1 mM activated sodium orthovanadate, 10 mM EDTA, 500 mM phenylmethanesulphonyl fluoride (all from Sigma-Aldrich) and Complete Mini protease inhibitor cocktail (Roche, Mannheim, Germany). Cellular proteins were resolved by SDS polyacrylamide gel electrophoresis before immunoblotting with antibodies against phosphorylated insulin receptor (Invitrogen, Carlsbad, CA, USA; 44804G), total insulin receptor (Santa Cruz Biotechnology, Santa Cruz, CA, USA; sc711), phosphorylated AKT (Cell Signalling, Danvers, MA, USA; 9271S), total AKT (Cell Signalling, 9272), phosphorylated ERK1/2 (Cell Signalling, 9106S), total ERK1/2 (Abcam, Cambs, UK; AB17942) or the p85 subunit of phosphoinositide 3-kinase (from Professor K Siddle, University of Cambridge). Statistical analyses were carried out in GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA), using analysis of variance with post hoc Tukey's tests for comparison between cell lines.
Alms1 mRNA was detectable in uninfected 3T3-L1 cells and decreased during adipocyte differentiation by around 50% (Figure 1a ), broadly consistent with previous studies. 12 In two independently derived sets of retrovirally infected 3T3-L1 preadipocytes, Alms1 mRNA expression was knocked down by around 80% compared to control cells, and this was sustained during adipogenesis ( Figure 1b) . Corroboration of knockdown at the protein level was not possible due to lack of an adequate antibody.
Alms1 knockdown modestly impaired adipocyte differentiation, as assessed both by Oil-Red-O staining of cellular triglyceride (Figure 1c) , and by a reduction of over 50% in transcript expression of a panel of key adipocyte genes, namely, Pparg2, Fabp4, Glut4, Insr and AdipoQ (Figure 1d ). Differentiation timecourses of gene expression further showed that the timing of adipocyte gene induction was unaffected by Alms1 deficiency, and that there was no evidence of convergence in adipocyte gene expression between cell lines when the differentiation time course was extended beyond 10 days (data not shown). The most likely interpretation of this in our view is that a smaller proportion of the Alms1 knockdown cells entered differentiation, rather than all cells entering differentiation with a slower trajectory.
Given the severity of IR in Alström syndrome, and the key role of microtubules in spatial organization of cell signalling and vesicle transport, we then evaluated the effect of Alms1 deficiency on insulin signalling. Knockdown of Alms1 had no effect on insulin-stimulated autophosphorylation of its receptor, nor phosphorylation of the key downstream kinases AKT and ERK1/2 (Figure 2a) . To assess the integrity of the whole signalling pathway between the insulin receptor and Glut4 vesicle fusion with the plasma membrane, we next examined insulin-stimulated glucose uptake. Whereas uptake by control cells increased tenfold on insulin stimulation, this increase was only six-to eightfold in Alms1-knockdown cells (Figure 2b ). However, this mild impairment in glucose uptake was approximately commensurate with the degree of impairment of differentiation, arguing against any additional cell-autonomous defect in insulin signal transduction in these cells.
The limited understanding of the molecular actions of Alms1 means that its role in adipogenesis is not clear.
Alms1 and adipogenesis I Huang-Doran and RK Semple
The early stages of 3T3-L1 differentiation are associated with two rounds of mitosisFso-called 'mitotic clonal expansion'Falthough the requirement of this phase for differentiation remains controversial. 13, 14 Given its centrosomal localization, Alms1 may have a role in these early cell divisions by participating in spindle formation or Figure 2 Knockdown of Alms1 results in mildly impaired insulin-stimulated glucose uptake with normal proximal insulin signalling in adipocytes. (a) Alms1-knockdown and control adipocytes were treated with 100 nM insulin for 5 min. Acute insulin-stimulated phosphorylation of insulin receptor, AKT and ERK was assessed by western blotting. Representative example of three independent experiments is shown. (b) Adipocytes were exposed to 100 nM insulin or PBS for 30 min, and 3 H-doxyglucose uptake by Alms1-knockdown and control adipocytes was determined. **Po0.01, ***Po0.005 vs insulin-treated shLuc control (n ¼ 11).
Alms1 and adipogenesis I Huang-Doran and RK Semple centrosome duplication. Alms1 is also found in basal bodies, centrosome-like structures that nucleate primary cilium formation, and early evidence suggests that adipogenesis is regulated by signalling pathways focussed on these cellular sensory 'antennae'. 15 Although primary cilia in cells from patients with Alström syndrome are grossly morphologically normal, a defect in their signalling function remains plausible in view of the many features of Alström syndrome shared by other ciliopathies such as the Bardet-Biedl syndromes. 16 Indeed loss of Alms1 expression in mice is associated with impaired primary cilia formation and function on renal epithelial cells. 17 In more general physiological terms, it remains to be determined whether the modest defect in adipogenesis that we observe in vitro is sufficient to account for severe IR in vivo. To maintain metabolic health in the face of caloric excess, adipose tissue is required to expand, through a combination of cellular hyperplasia and hypertrophy. 18 When this capacity is exceeded, the normal functions of adipose tissue become compromised, with consequent inflammation, hormonal dysregulation and fatty-acid spillover that together precipitate IR at other sites. 3, 19 Compromised adipose differentiation in Alström syndrome may thus produce severe IR by effectively reducing adipose tissue expandability, thereby lowering the threshold at which this 'fat failure' occurs. A prediction of this model would be that biopsy specimens from patients with Alström syndrome would show a larger adipocyte size, and increased evidence of secondary macrophage infiltration and adipose tissue 'stress'. However, this remains untested, and the degree of IR in Alström syndrome, commonly greater than that of congenital generalized lipodystrophy, suggests that other factors must also be at play. These could include defects in insulin action in other metabolically vital tissues such as skeletal muscle and liver. The multisystem fibrosis noted pathologically in Alström syndrome 4 also raises the possibility that alterations in adipose tissue extracellular matrix may introduce further constraints to adipose tissue expansion in vivo, which is known also to compromise the metabolic role of the tissue. 20 This aspect of adipose tissue dynamics is not modelled in our in vitro system. We have recently made the observation of a very high prevalence of extreme IR and dyslipidaemia in patients with genetic defects in PCNT, encoding pericentrin (RK Semple, personal observations). Similar to ALMS1, pericentrin is a very large pericentrosomal protein with a role in anchoring key components of the microtubule-organizing centre, and in coordinating signalling events at the centrosome. 21 This may begin to define a hitherto unappreciated role for the centrosome in maintaining metabolic homeostasis, and suggests that the severe IR of Alström syndrome reflects more than a unique function of the ALMS1 protein.
In summary, we have demonstrated that efficient knockdown of Alms1 expression modestly impairs differentiation of 3T3-L1 preadipocytes, but does not seem to affect cell-autonomous insulin action. Such data, with the further studies that are now required, will not only provide insights into the pathophysiology of a rare and extreme metabolic disorder, but may also provide a paradigm for understanding more prevalent metabolic disease.
